Increase in Chronic Diseases Despite Recovery from COVID-19 Pandemic

News by 2FIRSTS.ai
Dec.12.2023
Increase in Chronic Diseases Despite Recovery from COVID-19 Pandemic
According to Naver on December 7, after three years of the COVID-19 pandemic in South Korea, the proportion of chronic diseases such as overeating, obesity, and hypertension has increased.

According to a report by Naver on December 7th, despite the resumption of daily life and improvements in sports activities in South Korea after three years of the COVID-19 pandemic, there has been an increase in the prevalence of chronic diseases such as binge eating, obesity, and hypertension.

 

The "National Health and Nutrition Survey" is a survey conducted in accordance with the National Health Promotion Law, targeting individuals with an annual income of over 10,000 yuan. It covers over 250 public health indicators, including smoking, alcohol consumption, physical activity, nutrition, and chronic diseases.

 

The results indicate that although smoking rates have slightly declined in 2021, alcohol consumption rates have once again risen. Moreover, both men and women have shown an increase in participation in physical activities compared to last year.

 

The smoking rate among men last year was 36.6%, while it was 7.2% among women. The smoking rate for men remained the same as the previous year, while it decreased by 1.3 percentage points for women. Currently, the prevalence of smoking among men is 30%, while it is 5% among women, representing a decrease of 1.3 and 1.9 percentage points respectively compared to the previous year.

 

The smoking rate for vaping has seen a slight increase compared to last year, with 5.6% of men and 1.3% of women engaging in this activity. Additionally, there has been a growth in the use of heated tobacco products in the form of e-cigarettes (HNB products) as well. Among men, the usage rate has reached 9.2%, while for women it stands at 2.4%.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria to Tighten Sales Rules for Nicotine Pouches and E-Liquids From April 1
Austria will introduce new sales rules for nicotine products from April 1, 2026. Under a reform of the tobacco law passed in December 2025, nicotine pouches will in future be sold only through tobacco shops, while e-liquids will be sold only through tobacco shops and licensed specialist stores. Other points of sale will no longer be permitted to sell these products.
Mar.30 by 2FIRSTS.ai
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
From April 1, vape shops in Virginia may sell only liquid nicotine and vapor products listed in the state directory. The Office of the Attorney General has recommended that commonwealth attorneys begin enforcing the 2024 law.
Apr.02 by 2FIRSTS.ai
Smoore International Q1 Results: Enterprise-Focused Business Up 48.6% Year-on-Year, Proprietary E-Vapor Brand Business Up 14.3%
Smoore International Q1 Results: Enterprise-Focused Business Up 48.6% Year-on-Year, Proprietary E-Vapor Brand Business Up 14.3%
Smoore International reported its Q1 financial results, with revenue for the period reaching RMB3.856 billion, up 41.7% year-on-year, and net profit (profit for the period) totaling RMB262.5 million, up 36.6% year-on-year. Revenue from its enterprise-focused business was RMB3.2674 billion, representing a 48.6% increase from RMB2.1989 billion in the same period last year. Revenue from its proprietary brand business was RMB588.6 million, up 12.6% from RMB522.6 million a year earlier.
Apr.10 by 2FIRSTS.ai
 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea Names Lee Hong-seok as New CEO Effective May 1
Philip Morris Korea said on April 29 that it has appointed Lee Hong-seok, head of its smoke-free products division, as its new chief executive officer, with his term beginning on May 1. Yoon Hee-kyung, who took office in 2023, will step down after about three years in the role.
Apr.30 by 2FIRSTS.ai